Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 11 | 1 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Influenza A Virus, H1N1 Subtype Infections Overview | 15 | 1 |
| Pipeline Products for Influenza A Virus, H1N1 Subtype Infections Comparative Analysis | 16 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Therapeutics under Development by Companies | 17 | 3 |
| Influenza A Virus, H1N1 Subtype Infections Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Pipeline Products Glance | 21 | 3 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Products under Development by Companies | 24 | 4 |
| Influenza A Virus, H1N1 Subtype Infections Products under Investigation by Universities/Institutes | 28 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Companies Involved in Therapeutics Development | 29 | 36 |
| AbbVie Inc | 29 | 1 |
| Akshaya Bio Inc. | 30 | 1 |
| Altimmune, Inc. | 31 | 1 |
| Antigen Express, Inc. | 32 | 1 |
| Beijing Minhai Biotechnology Co., Ltd | 33 | 1 |
| CEL-SCI Corporation | 34 | 1 |
| Cilian AG | 35 | 1 |
| ContraFect Corporation | 36 | 1 |
| EpiVax, Inc. | 37 | 1 |
| Etubics Corporation | 38 | 1 |
| Gemmus Pharma Inc. | 39 | 1 |
| iBio, Inc. | 40 | 1 |
| ILiAD Biotechnologies, LLC | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 42 | 1 |
| Johnson &Johnson | 43 | 1 |
| Kineta, Inc. | 44 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 45 | 1 |
| Lakewood-Amedex Inc | 46 | 1 |
| Medicago Inc. | 47 | 1 |
| MedImmune, LLC | 48 | 1 |
| Microbiotix, Inc. | 49 | 1 |
| Mucosis B.V. | 50 | 1 |
| NanoViricides, Inc. | 51 | 1 |
| NewLink Genetics Corporation | 52 | 1 |
| OPKO Health, Inc. | 53 | 1 |
| PeptiDream Inc. | 54 | 1 |
| Recce Pty Ltd | 55 | 1 |
| Sarepta Therapeutics, Inc. | 56 | 1 |
| Takeda Pharmaceutical Company Limited | 57 | 1 |
| TechnoVax, Inc. | 58 | 1 |
| Touchlight Genetics Limited | 59 | 1 |
| Vaccibody AS | 60 | 1 |
| Vaxart, Inc. | 61 | 1 |
| Vironova AB | 62 | 1 |
| Visterra, Inc. | 63 | 1 |
| Zydus Cadila Healthcare Limited | 64 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Therapeutics Assessment | 65 | 10 |
| Assessment by Monotherapy Products | 65 | 1 |
| Assessment by Combination Products | 66 | 1 |
| Assessment by Target | 67 | 2 |
| Assessment by Mechanism of Action | 69 | 2 |
| Assessment by Route of Administration | 71 | 2 |
| Assessment by Molecule Type | 73 | 2 |
| Drug Profiles | 75 | 97 |
| A-06 Drug Profile | 75 | 1 |
| AEA-35p Drug Profile | 76 | 1 |
| Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza Drug Profile | 77 | 1 |
| Aspidasept Drug Profile | 78 | 1 |
| C-05 Drug Profile | 79 | 1 |
| CF-401 Drug Profile | 80 | 1 |
| CHOS-05 Drug Profile | 81 | 1 |
| CiFlu Drug Profile | 82 | 2 |
| CR-9114 Drug Profile | 84 | 1 |
| diridavumab Drug Profile | 85 | 2 |
| ETBX-051 Drug Profile | 87 | 1 |
| Fluad (quadrivalent) Drug Profile | 88 | 1 |
| Fludase Drug Profile | 89 | 3 |
| FluGEM Drug Profile | 92 | 1 |
| FVH-1 Drug Profile | 93 | 2 |
| Gamma-Flu Drug Profile | 95 | 1 |
| GP-1001 Drug Profile | 96 | 1 |
| GP-1681 Drug Profile | 97 | 2 |
| GREFLU/CAL Drug Profile | 99 | 1 |
| H1N1 [A/Aichi/2/68] vaccine Drug Profile | 100 | 1 |
| HB-36.6 Drug Profile | 101 | 1 |
| infectious disease vaccine Drug Profile | 102 | 1 |
| Influ-nRNA Drug Profile | 103 | 1 |
| influenza [strain A/H1N1] vaccine Drug Profile | 104 | 1 |
| influenza [strain A/H1N1] vaccine Drug Profile | 105 | 1 |
| influenza [strain A/H1N1] vaccine Drug Profile | 106 | 1 |
| influenza [strain H1N1] (monovalent) vaccine Drug Profile | 107 | 1 |
| influenza [strain H1N1] vaccine Drug Profile | 108 | 1 |
| influenza [strain H1N1] vaccine Drug Profile | 109 | 1 |
| influenza [strain H1N1] vaccine Drug Profile | 110 | 1 |
| influenza [strain H1N1] vaccine Drug Profile | 111 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile | 112 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile | 113 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile | 114 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine Drug Profile | 115 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile | 116 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile | 117 | 3 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile | 120 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine Drug Profile | 121 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile | 122 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile | 123 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile | 124 | 1 |
| influenza [strains A/H5N1 + A/H1N1] vaccine Drug Profile | 125 | 1 |
| influenza vaccine Drug Profile | 126 | 1 |
| INO-3510 Drug Profile | 127 | 2 |
| JNJ-872 Drug Profile | 129 | 3 |
| KIN-1400 Drug Profile | 132 | 2 |
| LEAPS-H1N1-DC Drug Profile | 134 | 1 |
| MBX-2329 Drug Profile | 135 | 1 |
| MBX-2546 Drug Profile | 136 | 1 |
| Nasovax Drug Profile | 137 | 2 |
| NEO-8877 Drug Profile | 139 | 1 |
| NVINF-1 Drug Profile | 140 | 4 |
| NVINF-2 Drug Profile | 144 | 3 |
| PD-001 Drug Profile | 147 | 1 |
| pertussis [strain BPZE1] vaccine Drug Profile | 148 | 2 |
| PNSIA-28 Drug Profile | 150 | 1 |
| PNSIA-49 Drug Profile | 151 | 1 |
| radavirsen Drug Profile | 152 | 2 |
| RECCE-327 Drug Profile | 154 | 1 |
| Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections Drug Profile | 155 | 1 |
| RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection Drug Profile | 156 | 1 |
| Small Molecules for Influenza A Virus H1N1 and H5N1 Infections Drug Profile | 157 | 1 |
| Small Molecules for RSV and Influenza A Infections Drug Profile | 158 | 1 |
| Small Molecules to Block M2 Channel for Influenza Infections Drug Profile | 159 | 1 |
| Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections Drug Profile | 160 | 1 |
| Synthetic Peptides for Influenza, HSV and HIV Infections Drug Profile | 161 | 1 |
| TVX-002 Drug Profile | 162 | 1 |
| VH-244 Drug Profile | 163 | 1 |
| VIS-410 Drug Profile | 164 | 3 |
| VNFC-045 Drug Profile | 167 | 1 |
| VNFC-051 Drug Profile | 168 | 1 |
| VXAA-1.1 Drug Profile | 169 | 2 |
| Z-3G1 Drug Profile | 171 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Dormant Projects | 172 | 4 |
| Influenza A Virus, H1N1 Subtype Infections Discontinued Products | 176 | 1 |
| Influenza A Virus, H1N1 Subtype Infections Product Development Milestones | 177 | 13 |
| Featured News &Press Releases | 177 | 1 |
| Aug 29, 2016: PaxVax Inks Swiss Marketing and Distribution Agreement with Seqirus for Influenza Vaccine Fluad (influenza vaccine, adjuvanted) | 177 | 1 |
| Aug 29, 2016: Seqirus receives FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older | 177 | 1 |
| Aug 25, 2016: VALNEVA Announces Signing of Marketing &Distribution Agreement for Seqirus' Flu vaccine Fluad in Austria | 178 | 1 |
| Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season | 179 | 1 |
| Feb 04, 2016: Fighting flu with designer drugs: A new compound fends off different influenza strains | 179 | 2 |
| Oct 08, 2015: Vaxart to Present Phase 1 Data at IDWeek 2015 Demonstrating Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses | 181 | 1 |
| Aug 23, 2015: Vaxart Announces Lancet ID Publication of Influenza Tablet Vaccine Phase 1 Results | 181 | 1 |
| Jul 07, 2015: Ansun BioPharma Publishes Effects of FluDase on Drug Resistant Flu | 182 | 1 |
| Oct 14, 2014: Vaxart s Tablet Vaccine for H1N1 Influenza Generates Protective Immunity Equivalent to Injectable in Phase I Clinical Study | 182 | 1 |
| Jul 14, 2014: NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference held by GTC Bio on Friday, July 11 | 183 | 1 |
| Apr 30, 2014: Etubics And University Of Texas Medical Branch Awarded Grant For Development Of Universal Influenza Vaccine | 184 | 1 |
| Jan 09, 2014: Vaxart s Oral H1N1 Influenza Vaccine Generates Protective Immunity | 185 | 1 |
| Apr 18, 2013: Inovio Pharma's Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable To Conventional Vaccine In Phase I Study | 186 | 1 |
| Feb 22, 2013: Discovery of New Antivirals That Block the Progression of the Flu Virus | 187 | 1 |
| Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 | 188 | 2 |
| Appendix | 190 | 2 |
| Methodology | 190 | 1 |
| Coverage | 190 | 1 |
| Secondary Research | 190 | 1 |
| Primary Research | 190 | 1 |
| Expert Panel Validation | 190 | 1 |
| Contact Us | 190 | 1 |
| Disclaimer | 191 | 1 |